News & Events

Learn more about ReForm Biologics and our commitment to innovation in biotherapeutics.


ReForm Biologics Announces New Patent on Surfactant Replacement Excipients to Stabilize Antibody-Based Therapeutics

New surfactant replacement offers a promising alternative to polysorbates for stabilizing proteins

Read More >

ReForm Biologics and KBI Biopharma Announce Strategic Partnership to Improve Biopharmaceutical Formulations and Development

Collaboration will provide clients competitive advantages, improve speed to market 

KBI makes equity investment in ReForm Biologics along with existing investors

ReForm Biologics and KBI Biopharma, Inc., (KBI) today announced a strategic partnership to make improved biopharmaceutical formulations.

Read More >

ReForm Biologics Secures New Patent Expanding Coverage of Key Excipient Formulation for Antibody-Based Therapeutics

ReForm Biologics, a pharmaceutical technology company developing innovative platforms to improve biologic formulations, expanded its patent portfolio with the issuance of U.S. Patent No. 9,867,881 (the ‘881 patent).

Read More >

ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics

ReForm Biologics to present at the 13th annual PEGS Summit

ReForm Biologics, a pharmaceutical technology company developing an innovative platform to improve biologic formulations, announced today the issuance of U.S. patent 9,605,051 (the ‘051 patent) for one of its new excipient formulations.

Read More >

ReForm Biologics Appoints John M. Sorvillo, Ph.D., as Chief Executive Officer

Dr. Sorvillo brings over 25 years of experience leading the development and licensing of technologies, from discovery platforms and research programs to pre-clinical and clinical products, across a range of therapeutic areas.

Read More >